TREATMENT OF METASTATIC MELANOMA WITH INTERLEUKIN-2

被引：0
作者：
CHOSIDOW, O
GUILLAUME, JC
机构：
[1] HOP HENRI MONDOR,SERV DERMATOL,F-94010 CRETEIL,FRANCE
[2] INST GUSTAVE ROUSSY,SERV DERMATOL,F-94805 VILLEJUIF,FRANCE
来源：
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE | 1992年 / 119卷 / 01期
关键词：
MALIGNANT MELANOMA; INTERLEUKIN-2;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：65 / 73
页数：9
相关论文
共 50 条
[41]   Outpatient experience with moderate dose bolus interleukin-2 in metastatic malignant melanoma and kidney cancer [J].
Quan, WDY ;
Quan, FM .
JOURNAL OF IMMUNOTHERAPY, 2003, 26 (03) :286-290
[42]   Treatment of pediatric ocular melanoma with high-dose interleukin-2 and thalidomide [J].
Soni, S ;
Lee, DS ;
DiVito, J ;
Bui, AH ;
DeRaffele, G ;
Radel, E ;
Kaufman, HL .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2002, 24 (06) :488-491
[43]   Subcutaneous interleukin-2 and interferon in the treatment of patients with metastatic renal cell carcinoma -: Less efficacy compared with intravenous interleukin-2 and interferon α [J].
Ravaud, A ;
Delva, R ;
Gomez, F ;
Chevreau, C ;
Douillard, JY ;
Peny, J ;
Coudert, B ;
Négrier, S .
CANCER, 2002, 95 (11) :2324-2330
[44]   Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma [J].
Hughes, Tasha ;
Klairmont, Matthew ;
Sharfman, William H. ;
Kaufman, Howard L. .
CANCER BIOLOGY & THERAPY, 2021, 22 (10-12) :513-526
[45]   Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy [J].
Pim P. van de Donk ;
Thijs T. Wind ;
Jahlisa S. Hooiveld-Noeken ;
Elly L. van der Veen ;
Andor W. J. M. Glaudemans ;
Arjan Diepstra ;
Mathilde Jalving ;
Elisabeth G. E. de Vries ;
Erik F. J. de Vries ;
Geke A. P. Hospers .
European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 :4369-4376
[46]   ADDITION OF DACARBAZINE OR CISPLATIN TO INTERFERON-ALPHA INTERLEUKIN-2 IN METASTATIC MELANOMA - TOXICITY AND IMMUNOLOGICAL EFFECTS [J].
KEILHOLZ, U ;
SCHEIBENBOGEN, C ;
MOHLER, T ;
BROSSART, P ;
MACLACHLAN, D ;
GEUEKE, AM ;
JOCHIM, A ;
HUNSTEIN, W .
MELANOMA RESEARCH, 1995, 5 (04) :283-287
[47]   High-dose interleukin-2 in patients with metastatic melanoma whose disease progressed after biochemotherapy [J].
Buzaid, Antonio Carlos ;
Schmerling, Rafael Aron ;
Vieira Guedes, Rodrigo Antonio ;
de Freitas, Daniela ;
William, William Nassib, Jr. .
MELANOMA RESEARCH, 2011, 21 (04) :370-375
[48]   Decreased tolerance to interleukin-2 with repeated courses of therapy in patients with metastatic melanoma or renal cell cancer [J].
Marroquin, CE ;
White, DE ;
Steinberg, SM ;
Rosenberg, SA ;
Schwartzentruber, DJ .
JOURNAL OF IMMUNOTHERAPY, 2000, 23 (03) :387-392
[49]   Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma [J].
Masucci, Giuseppe Valentino ;
Mansson-Brahme, Eva ;
Ragnarsson-Olding, Boel ;
Nilsson, Bo ;
Wagenius, Gunnar ;
Hansson, Johan .
MELANOMA RESEARCH, 2006, 16 (04) :357-363
[50]   Interleukin-2 enhances the growth of human melanoma cells derived from primary but not from metastatic tumours [J].
García-Vázquez, MD ;
Boyano, MD ;
Cañavate, ML ;
Gardeazabal, J ;
De Galdeano, AG ;
López-Michelena, T ;
Ratón, JA ;
Izu, R ;
Díaz-Ramón, JL ;
Díaz-Pérez, JL .
EUROPEAN CYTOKINE NETWORK, 2000, 11 (04) :654-661
12345